Technical Analysis for SAR - Sareum Holdings Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -0.41% | |
| NR7 | Range Contraction | -0.41% | |
| NR7-2 | Range Contraction | -0.41% | |
| Narrow Range Bar | Range Contraction | -0.41% | |
| Wide Bands | Range Expansion | -0.41% | |
| Calm After Storm | Range Contraction | -7.05% | |
| NR7 | Range Contraction | -7.05% | |
| Narrow Range Bar | Range Contraction | -7.05% | |
| Inside Day | Range Contraction | -7.05% | |
| Wide Bands | Range Expansion | -7.05% |
| Alert | Time |
|---|---|
| Possible NR7 | about 2 hours ago |
| Fell Below 50 DMA | about 3 hours ago |
| Down 2% | about 4 hours ago |
| Down 1% | about 4 hours ago |
| 50 DMA Support | about 4 hours ago |
Get this analysis on your stocks daily!
Sareum Holdings Plc Description
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Cancer Disease Branches Of Biology Drugs Diseases Biology Radio Therapy Autoimmune Diseases Blood Disorders Cancers Skills Enzymes Rheumatoid Arthritis Acute Myeloid Leukemia Arthritis Chemotherapy Medicinal Chemistry Psoriasis Acute Lymphoblastic Leukemia Head And Neck Cancers Inflammatory Disorders Kinase Leukemia Radiotherapy Tyrosine Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 149.0 |
| 52 Week Low | 10.0 |
| Average Volume | 1,558,182 |
| 200-Day Moving Average | 58.50 |
| 50-Day Moving Average | 24.26 |
| 20-Day Moving Average | 18.87 |
| 10-Day Moving Average | 25.18 |
| Average True Range | 4.13 |
| RSI (14) | 53.49 |
| ADX | 41.24 |
| +DI | 37.17 |
| -DI | 19.28 |
| Chandelier Exit (Long, 3 ATRs) | 25.42 |
| Chandelier Exit (Short, 3 ATRs) | 22.38 |
| Upper Bollinger Bands | 33.27 |
| Lower Bollinger Band | 4.46 |
| Percent B (%b) | 0.7 |
| BandWidth | 152.70 |
| MACD Line | 1.49 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 1.5737 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.24 | ||||
| Resistance 3 (R3) | 27.50 | 26.85 | 26.78 | ||
| Resistance 2 (R2) | 26.85 | 26.15 | 26.72 | 26.63 | |
| Resistance 1 (R1) | 25.68 | 25.72 | 25.35 | 25.41 | 26.48 |
| Pivot Point | 25.03 | 25.03 | 24.86 | 24.89 | 25.03 |
| Support 1 (S1) | 23.85 | 24.33 | 23.53 | 23.59 | 22.52 |
| Support 2 (S2) | 23.20 | 23.90 | 23.07 | 22.37 | |
| Support 3 (S3) | 22.03 | 23.20 | 22.22 | ||
| Support 4 (S4) | 21.76 |
